Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Insmed Incorporated or Xenon Pharmaceuticals Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Insmed Incorporated and Xenon Pharmaceuticals Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Insmed Incorporated and Xenon Pharmaceuticals Inc.

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company’s Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Latest Biotechnology and Insmed Incorporated, Xenon Pharmaceuticals Inc. Stock News

As of September 4, 2026, Insmed Incorporated had a $27.6 billion market capitalization, compared to the Biotechnology median of $282.4 million. Insmed Incorporated’s stock is down 27.4% in 2026, up 6.5% in the previous five trading days and down 11.39% in the past year.

Currently, Insmed Incorporated does not have a price-earnings ratio. Insmed Incorporated’s trailing 12-month revenue is $1.1 billion with a -76.9% net profit margin. Year-over-year quarterly sales growth most recently was 296.2%. Analysts expect adjusted earnings to reach $-1.554 per share for the current fiscal year. Insmed Incorporated does not currently pay a dividend.

As of September 4, 2026, Xenon Pharmaceuticals Inc. had a $5.8 billion market cap, putting it in the 69th percentile of all stocks. Xenon Pharmaceuticals Inc.’s stock is up 33.3% in 2026, down 0.4% in the previous five trading days and up 54.63% in the past year.

Currently, Xenon Pharmaceuticals Inc. does not have a price-earnings ratio. Xenon Pharmaceuticals Inc.’s trailing 12-month revenue is $0.0 million with a % net profit margin. As of September 4, 2026, Xenon Pharmaceuticals Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-4.633 per share for the current fiscal year. Xenon Pharmaceuticals Inc. does not currently pay a dividend.

How We Compare Insmed Incorporated and Xenon Pharmaceuticals Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Insmed Incorporated and Xenon Pharmaceuticals Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Insmed Incorporated and Xenon Pharmaceuticals Inc. Growth Grades

Company	Ticker	Growth
Insmed Incorporated	INSM	D
Xenon Pharmaceuticals Inc.	XENE	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Insmed Incorporated has a Growth Score of 29, which is Weak. Xenon Pharmaceuticals Inc. has a Growth Score of 0, which is Very Weak.

The Growth Stock Winner: No Clear Winner

Neither Insmed Incorporated or Xenon Pharmaceuticals Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Insmed Incorporated or Xenon Pharmaceuticals Inc. is the better investment when it comes to sustainable growth.

Insmed Incorporated and Xenon Pharmaceuticals Inc.’s Quality Grades

Company	Ticker	Quality
Insmed Incorporated	INSM	D
Xenon Pharmaceuticals Inc.	XENE	D

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Insmed Incorporated has a Quality Score of 30, which is Weak. Xenon Pharmaceuticals Inc. has a Quality Score of 27, which is Weak.

The Quality Stock Winner: No Clear Winner

Neither Insmed Incorporated or Xenon Pharmaceuticals Inc. has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Insmed Incorporated or Xenon Pharmaceuticals Inc. is the better investment when it comes to quality.

Insmed Incorporated and Xenon Pharmaceuticals Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Insmed Incorporated	INSM	B
Xenon Pharmaceuticals Inc.	XENE	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Insmed Incorporated has a Earnings Estimate Score of 75, which is Positive. Xenon Pharmaceuticals Inc. has a Earnings Estimate Score of 54, which is Neutral.

The Earnings Estimate Revisions Grade Winner: Insmed Incorporated

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Insmed Incorporated has a better Earnings Estimate Revisions Grade than Xenon Pharmaceuticals Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Insmed Incorporated could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Insmed Incorporated and Xenon Pharmaceuticals Inc. Grades

In addition to Quality, Estimate Revisions and Growth, A+ Investor also provides grades for Value and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Insmed Incorporated and Xenon Pharmaceuticals Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Insmed Incorporated or Xenon Pharmaceuticals Inc. Stock?

Overall, Insmed Incorporated stock has a Growth Score of 29, Estimate Revisions Score of 75 and Quality Score of 30.

Xenon Pharmaceuticals Inc. stock has a Growth Score of 0, Estimate Revisions Score of 54 and Quality Score of 27.

Comparing Insmed Incorporated and Xenon Pharmaceuticals Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.